Enanta Pharmaceuticals | ENTA - Ebitda

Stock Price
12.20
Daily Change
0.12 0.99%
Monthly
-15.34%
Yearly
108.19%
Q1 Forecast
12.13

Enanta Pharmaceuticals reported $-36.06M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
AstraZeneca USD 5.23B 272M Sep/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Incyte USD 414.5M 92.42M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
J&J USD 9.52B 389M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 4.77B 1.11B Dec/2025
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025